Most skin cancers are not fatal, but the answer depends entirely on the type and how early it’s caught. Basal cell carcinoma, the most common form, almost never kills. Squamous cell carcinoma carries a slightly elevated mortality risk. Melanoma is the dangerous one: it accounts for the vast majority of skin cancer deaths, with an estimated 8,510 Americans expected to die from it in 2026 alone. Even melanoma, though, has a five-year survival rate above 99% when caught early.
Basal Cell and Squamous Cell Carcinoma
Basal cell carcinoma makes up roughly 80% of all skin cancers, and it is extremely unlikely to kill you. A large retrospective study found no significant increase in mortality for people diagnosed with basal cell carcinoma compared to the general population. These tumors grow slowly and rarely spread beyond the skin. They can cause local tissue damage if ignored for years, but death from basal cell carcinoma is exceptionally rare.
Squamous cell carcinoma is the second most common type and slightly more dangerous. The same study found a 25% higher risk of death compared to matched controls, even after excluding people who later developed melanoma. That said, the absolute risk remains low. Most squamous cell carcinomas are removed with a simple procedure and never return. The ones that become life-threatening tend to occur in people with weakened immune systems or in tumors that grow in certain locations like the ear, lip, or areas of chronic scarring.
Melanoma: The Numbers by Stage
Melanoma is responsible for the overwhelming majority of skin cancer deaths despite being far less common than basal or squamous cell types. An estimated 112,000 new cases will be diagnosed in the U.S. in 2026. How fatal it is depends almost entirely on how far the cancer has progressed at the time of diagnosis.
For localized melanoma, meaning the cancer is still confined to the skin where it started, the five-year survival rate is above 99%. Once it spreads to nearby lymph nodes (regional stage), survival drops to 76%. If it reaches distant organs like the lungs, liver, or brain, the five-year survival rate falls to 35%. Overall, using older SEER data that captures longer follow-up periods, those numbers break down to 97.6% for localized, 60.3% for regional, and 16.2% for distant stage disease.
The difference between these two sets of numbers reflects real progress. Newer treatments have substantially improved outcomes, particularly for advanced cases.
Why Thickness Matters So Much
The single most important factor in predicting whether a melanoma will be fatal is how deep it has grown into the skin at the time it’s removed. This measurement, taken in millimeters, directly correlates with the likelihood the cancer has already begun to spread.
Melanomas thinner than 1 millimeter are considered early stage and carry excellent survival odds. Between 1 and 2 millimeters, the risk of spread starts to increase. Between 2 and 4 millimeters, the cancer is considerably more dangerous. Above 4 millimeters, the prognosis worsens significantly. A melanoma that’s caught at the thickness of a credit card edge is a fundamentally different disease than one that has grown several millimeters deep. This is why changes in a mole’s size, color, or shape matter: they’re visible clues that a tumor may be thickening.
How Immunotherapy Changed Advanced Melanoma
A decade ago, a stage IV melanoma diagnosis was nearly a death sentence. Median survival was just 8.3 months, and only about 14% of patients survived five years. The introduction of immunotherapy drugs that help the immune system recognize and attack cancer cells has transformed those numbers. Median survival for stage IV melanoma has doubled to 15.2 months, and the five-year survival rate has risen to 31%.
For stage III melanoma, the improvement is even more dramatic. Five-year survival climbed from 55% to 67%, and the median overall survival went from about seven years to a point that hasn’t even been reached yet, meaning more than half of patients are still alive at the end of the study period. These gains are real and meaningful, though disparities in outcomes persist across racial and socioeconomic groups, with Black and lower-income patients seeing less benefit from these advances.
Merkel Cell Carcinoma: A Rarer Threat
Merkel cell carcinoma is far less common than melanoma but worth knowing about. This aggressive cancer typically appears as a painless, firm bump on sun-exposed skin, often in older adults. The five-year survival rate is 79% for localized disease, 66% for regional spread, and 31% for distant metastasis. Its overall five-year survival of 69% makes it more lethal stage-for-stage than many other skin cancers. Because it’s rare and can look unremarkable, it’s often diagnosed later than it should be.
What Makes the Difference Between Fatal and Curable
The gap between a skin cancer that’s a minor inconvenience and one that kills comes down to timing. A localized melanoma caught early is curable with surgery in the vast majority of cases. The same melanoma caught six months or a year later, after it has grown deeper and seeded itself into lymph nodes or organs, becomes a far more serious problem. The survival rate drops from above 99% to as low as 35% once the disease reaches distant sites.
For basal and squamous cell carcinomas, the calculus is simpler. Nearly all of them are cured with removal. The small fraction that become dangerous are typically ones that went untreated for a long time or occurred in immunocompromised patients. Melanoma is the type where vigilance genuinely saves lives, because the window between “easily curable” and “potentially fatal” can be surprisingly narrow. A new or changing spot on your skin that looks different from the others around it is worth having examined, not because skin cancer is likely to kill you, but because catching the rare dangerous one early is the single biggest factor in making sure it doesn’t.